Skip to main content

Advertisement

SpringerLink
Log in

Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

HIV-infected men who have sex with men remain at high risk of developing anal cancer despite the widespread use of highly active antiretroviral therapy (HAART). In HIVinfected women, however, there is some evidence that HAART may be associated with regression of human papillomavirus (HPV)-related cervical disease. So far, epidemiologic data provided by cancer registries have shown no reduction in the incidence of cervical and anal cancer in patients with HIV infection since the initiation of HAART in 1996. Recent data suggest that HPV infection occurs in the anal canal of immunocompromised patients, as an opportunistic infection, in the absence of receptive anal intercourse. Taken together, these lines of evidence support the need for developing anal and cervical cancer screening programs for patients with HIV, whether untreated or on HAART.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ellerbrock TV, Chiasson MA, Bush TJ, et al.: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000, 283:1031–1037.

    Article  PubMed  CAS  Google Scholar 

  2. Palefsky JM, Holly EA, Hogeboom CJ, et al.: Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIVpositive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 7:314–319.

    Google Scholar 

  3. Murphy EL, Collier AC, Kalish LA, et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135:17–26.

    PubMed  CAS  Google Scholar 

  4. Mocroft A, Katlama C, Johnson AM, et al.: AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000, 356:291–296.

    Article  PubMed  CAS  Google Scholar 

  5. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.

    Article  PubMed  Google Scholar 

  6. Lee LM, Karon JM, Selik R, et al.: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 2001, 285:1308–1315.

    Article  PubMed  CAS  Google Scholar 

  7. Lewden C, Raffi F, Chene G, et al.: Mortality in a cohort of HIVinfected adults started on a protease inhibitor-containing therapy: standardization to the general population. J Acquir Immune Defic Syndr 2001, 26:480–482.

    PubMed  CAS  Google Scholar 

  8. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112–116.

    Article  PubMed  CAS  Google Scholar 

  9. Havlir DV, Schrier RD, Torriani FJ, et al.: Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000, 182:1658–1663.

    Article  PubMed  CAS  Google Scholar 

  10. Komanduri KV, Viswanathan MN, Wieder ED, et al.: Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998, 4:953–956.

    Article  PubMed  CAS  Google Scholar 

  11. Schuman P, Ohmit SE, Klein RS, et al.: Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003, 188:128–136.

    Article  PubMed  Google Scholar 

  12. Uberti-Foppa C, Ferrari D, Lodini S, et al.: Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. AIDS 2003, 17:2136–2138.

    Article  PubMed  Google Scholar 

  13. Ahdieh-Grant L, Li R, Levine AM, et al.: Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004, 96:1070–1076. This study showed that HAART use was associated with increased regression of SIL among HIV-infected women with normal cervical cytology at baseline and subsequently diagnosed during 7 years of follow-up with incident cervical SIL.

    Article  PubMed  CAS  Google Scholar 

  14. Del Mistro A, Bertorelle R, Franzetti M, et al.: Antiretroviral therapy and the clinical evolution of human papillomavirusassociated genital lesions in HIV-positive women. Clin Infect Dis 2004, 38:737–742.

    Article  PubMed  Google Scholar 

  15. Moore AL, Sabin CA, Madge S, et al.: Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS 2002, 16:927–929.

    Article  PubMed  Google Scholar 

  16. Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002, 16:1799–1802.

    Article  PubMed  CAS  Google Scholar 

  17. Robinson WR, Hamilton CA, Michaels SH, Kissinger P: Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001, 184:538–543.

    Article  PubMed  CAS  Google Scholar 

  18. Minkoff H, Ahdieh L, Massad LS, et al.: The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001, 15:2157–2164.

    Article  PubMed  CAS  Google Scholar 

  19. Lillo FB, Ferrari D, Veglia F, et al.: Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001, 184:547–551.

    Article  PubMed  CAS  Google Scholar 

  20. Orlando G, Fasolo MM, Signori R, et al.: Impact of highly active antiretroviral therapy on clinical evolution of genital warts in HIV-infected patients. AIDS 1999, 13:291–293.

    Article  PubMed  CAS  Google Scholar 

  21. Heard I, Schmitz V, Costagliola D, et al.: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998, 12:1459–1464.

    Article  PubMed  CAS  Google Scholar 

  22. Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500–1510.

    Article  PubMed  CAS  Google Scholar 

  23. Franceschi S, Dal Maso L, Pezzotti P, et al.: Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. J Acquir Immune Defic Syndr 2003, 34:84–90.

    Article  PubMed  Google Scholar 

  24. Dorrucci M, Suligoi B, Serraino D, et al.: Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 26:377–380.

    PubMed  CAS  Google Scholar 

  25. Palefsky JM, Holly EA, Ralston ML, et al.: Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001, 28:422–428.

    PubMed  CAS  Google Scholar 

  26. Palefsky JM, Holly EA, Ralston ML, et al.: Effect of HAART on prevalence of anal intraepithelial neoplasia 2 and 3. Paper presented at the Sixth International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD, April 22–24, 2002.

  27. Palefsky JM, Holly EA, Ralston ML, et al.: Effect of HAART on incidence of anal intraepithelial neoplasia grade 3 among HIV-positive men who have sex with men. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, July 7–12, 2002.

  28. Piketty C, Darragh TM, Heard I, et al.: High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite use of highly active antiretroviral therapy. Sex Transm Dis 2004, 31:96–99.

    Article  PubMed  Google Scholar 

  29. Kiviat N, Redman MW, Hawes SE, et al.: The effect of HAART on detection of anal HPV and squamous intraepithelial lesions among HIV-infected homosexual men. Paper presented at the 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD, April 22–24, 2002.

  30. Wilkin TJ, Palmer S, Brudney KF, et al.: Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 2004, 190:1685–1691.

    Article  PubMed  CAS  Google Scholar 

  31. Kadish AS, Timmins P, Wang Y, et al.: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002, 11:483–488.

    PubMed  CAS  Google Scholar 

  32. Hopfl R, Heim K, Christensen N, et al.: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000, 356:1985–1986.

    Article  PubMed  CAS  Google Scholar 

  33. Nakagawa M, Stites DP, Patel S, et al.: Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000, 182:595–598.

    Article  PubMed  CAS  Google Scholar 

  34. Nakagawa M, Stites DP, Farhat S, et al.: Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997, 175:927–931.

    Article  PubMed  CAS  Google Scholar 

  35. Kadish AS, Ho GY, Burk RD, et al.: Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997, 89:1285–1293.

    Article  PubMed  CAS  Google Scholar 

  36. Einstein MH, Kadish AS: Anogenital neoplasia in AIDS. Curr Opin Oncol 2004, 16:455–462.

    Article  PubMed  Google Scholar 

  37. Goedert JJ, Cote TR, Virgo P, et al.: Spectrum of AIDS-associated malignant disorders. Lancet 1998, 351:1833–1839.

    Article  PubMed  CAS  Google Scholar 

  38. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000, 27:390–401.

    PubMed  CAS  Google Scholar 

  39. Diamond C, Taylor TH, Culver HA: Dramatic increase in anal cancer diagnoses in the era of highly active antiretroviral therapy. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8–11, 2004.

  40. Bower M, Powles T, Newsom-Davis T, et al.: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004, 37:1563–1565. kThis study indicated that in a large cohort of HIV-infected patients, there has been no significant change in the incidence, clinical features, or overall survival of anal cancer since the introduction of HAART.

    Article  PubMed  Google Scholar 

  41. Blohme I, Brynger H: Malignant disease in renal transplant patients. Transplantation 1985, 39:23–25.

    PubMed  CAS  Google Scholar 

  42. Ogunbiyi OA, Scholefield JH, Raftery AT, et al.: Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg 1994, 81:365–367.

    Article  PubMed  CAS  Google Scholar 

  43. Penn I: Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986, 58:611–616.

    Article  PubMed  CAS  Google Scholar 

  44. Williams AB, Darragh TM, Vranizan K, et al.: Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virusinfected women. Obstet Gynecol 1994, 83:205–211.

    PubMed  CAS  Google Scholar 

  45. Holly EA, Ralston ML, Darragh TM, et al.: Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001, 93:843–849.

    Article  PubMed  CAS  Google Scholar 

  46. Drobacheff C, Dupont P, Mougin C, et al.: Anal human papillomavirus DNA screening by Hybrid Capture II in human immunodeficiency virus-positive patients with or without anal intercourse. Eur J Dermatol 2003, 13:367–371.

    PubMed  CAS  Google Scholar 

  47. Piketty C, Darragh TM, Da Costa M, et al.: High prevalence of anal HPV infection and anal cancer precursors among HIV-infected individuals in the absence of anal intercourse. Ann Intern Med 2003, 183:453–459. This cross-sectional study included HIV-infected men who were injection drug users or had sex with men. It showed a high prevalence of anal intraepithelial neoplasia and HPV infection in HIV-infected men, regardless of history of anal intercourse.

    Google Scholar 

  48. Palefsky JM: Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr 1998, 23:15–20.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’Immunologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France

    Christophe Piketty MD, PhD & Michel D. Kazatchkine MD, PhD

Authors
  1. Christophe Piketty MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel D. Kazatchkine MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piketty, C., Kazatchkine, M.D. Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep 2, 140–145 (2005). https://doi.org/10.1007/s11904-005-0007-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-005-0007-5

Keywords

Search

Navigation